Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

103.31 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by... 
Via FinancialNewsMedia
Exposures COVID-19
Two Appealing Biotech Stocks for Two Distinct investors
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates
Via ACCESSWIRE
Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses
Via ACCESSWIRE
3 Health Care Stocks in Great Financial Health
Health care’s potential to do better in both up and down markets makes it a valuable part of a long-term investment strategy. 
Via MarketBeat
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses
Via ACCESSWIRE
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses
New U.S. government contract includes an award up to $1.74 billion for 66 million doses to be delivered in 2022; additional options, if exercised, may raise total to 300 million doses 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Is Moderna's Cheaper Valuation A Buying Signal?
Moderna is one of the least expensive companies in the S&P 500 in terms of valuation. In this article, we'll examine other aspects of the company. 
Via MarketBeat
Topics Stocks
Exposures US Equities
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
Via ACCESSWIRE
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
CAMBRIDGE, MA / ACCESSWIRE / July 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Therapeutic Goods Administration Grants Provisional Approval for Moderna's COVID-19 Vaccine in Children Aged Six Months to Five Years
Via ACN Newswire
Exposures COVID-19
Is it Time to Cash Out Novavax Stock?
Vaccine developer Novavax (NASDAQ: NVAX) stock has collapsed (-61%) in 2022. The Company’s protein-based COVID-19 vaccine Nuvaxovid has launched in Europe and awaits CDC approval for launch the U.S. 
Via MarketBeat
Exposures COVID-19 Product Safety
Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years
Via ACCESSWIRE
Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years
Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Argentina, Canada, Israel, the US, and Taiwan for active immunization to prevent COVID-19 caused by SARS-CoV-2 in... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Hold Pfizer Today With Catalysts for Further Growth Tomorrow
Pfizer stock is down 12% in 2022. However, there is one short-term and one long-term catalyst that should inform your decision on whether PFE stock is right for your investment objectives. 
Via MarketBeat
Exposures COVID-19 Product Safety
Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)
Two-dose series takes one month to complete, with similar vaccine efficacy estimates against Omicron to those seen in adults 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna to Report First Quarter Financial Results on Wednesday, August 3, 2022
CAMBRIDGE, MA / ACCESSWIRE / July 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live... 
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Moderna Announces First Participant Dosed in a Phase 1 Trial of its Nipah Virus mRNA Vaccine, mRNA-1215
Moderna advances global health commitment with mRNA vaccine candidate against the Nipah virus, a lethal pathogen with pandemic potential 
From Moderna, Inc.
Via AccessWire
Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared To Currently Authorized Booster
mRNA-1273.214 has now demonstrated significantly higher antibody titers against all tested variants, including Omicron BA.1 and BA.4/5 subvariants, ancestral virus, Alpha, Beta, Delta, and Gamma 
From Moderna, Inc.
Via AccessWire
Exposures Product Safety
3 Growth Stocks Trading at Value P/E's
The depressed P/E ratios of these three S&P 500 growth stocks make them value stocks in a growth wrapper—and bargain buys for investors. 
Via MarketBeat
Topics Economy Stocks
Exposures Economy US Equities
Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5
mRNA-1273.214 Exhibited a Greater Than 5-Fold Boost in Neutralizing Antibodies Against BA.4 and BA.5 Subvariants in Phase 2/3 Study 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom
Manufacturing facility would provide access to domestically manufactured vaccines against respiratory viruses 
From Moderna, Inc.
Via AccessWire
Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older
mRNA-1273 was authorized for children and adolescents aged 6 months through 17 years of age, administered as two doses given one month apart 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron
Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant 
From Moderna, Inc.
Via AccessWire
Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
mRNA-1010 is Moderna's first seasonal influenza vaccine candidate to enter a Phase 3 trialmRNA-1010 is one of several influenza vaccine candidates being developed in Moderna's respiratory... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement
CAMBRIDGE, MA / ACCESSWIRE / June 2, 2022 / Moderna, Inc.(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the European... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna to Present at Upcoming Conferences in June 2022
CAMBRIDGE, MA / ACCESSWIRE / June 1, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the... 
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
From Takeda Pharmaceutical Company Limited
Via Business Wire
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna to Present at the UBS 2022 Global Healthcare Conference
CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a... 
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.